Protalix BioTherapeutics, Inc. Net Fee Amt
Protalix BioTherapeutics, Inc. (PLX) had Net Fee Amt of $1.18 thousand as of 2026-08-11, per its S-8 filed 2026-08-12.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-12
- 2026-08-11: Net Fee Amt $1.18K.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-11 | $1.18K S-8 · filed 2026-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |